Loading stock data…
HSCS
$1.99+0.04 (+2.05%)
Market ClosedLast close May 1
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
HeartSciences Inc. in the Healthcare sector is trading at $1.99. The stock is currently near its 52-week low of $1.89, remaining 33.7% below its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why HSCS maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.99
Potential Upside
5%
Whystock Fair Value$2.09
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.50M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.45
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-251.55%
Volume
Today's trading volume
5,794
Recent News
HeartSciences Inc. (HSCS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for HeartSciences Inc. (HSCS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
HeartSciences recesives FDA BDD for Aortic Stenosis ECG algorithm
HeartSciences (HSCS) announced that the U.S. Food and Drug Administration has granted Breakthrough Device designationless than BDD, for its Aortic Stenosis ECG algorithm. The algorithm would offer a novel, AI-driven ECG solution capable of detecting moderate-to-severe aortic stenosis. Once cleared by the FDA, the algorithm will be accessible through HeartSciences’ MyoVista Insights cloud-based platform which would directly integrate with hospital electronic health record systems, requiring no ad
HeartSciences signs first MyoVista Insights platform customer
HeartSciences (HSCS) announced the signing of its first commercial customer for the MyoVista Insights platform: Westcliffe Health Innovations, based in the United Kingdom. This milestone follows the recent launch of MyoVista Insights and the initiation of an early adopter program for reference sites earlier this month. Westcliffe Health Innovations provides cardiology services to the U.K. National Health Service in the Bradford and Leeds region. As the largest publicly funded healthcare system i